← Leaderboards
David A. Horne
Oregon State University
$4,611,324
Attributed
$6,097,849
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,097,849 · 8
By mechanism
U01$2,973,050 · 2
R01$1,901,690 · 3
P30$1,223,109 · 3
Top collaborators
- Binghui Shen3 shared
- Donald E Mager2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsPharmaceutical PreparationsSmall MoleculeBiologicalCellsEnzymesPre-ClinicalClinical TrialsNovel TherapeuticsPathway InteractionsSolid NeoplasmCancer Center Support GrantNerve Stem CellCyclic GmpStem CellsPhase I Clinical TrialsCollaborationsResearch PersonnelMolecularMemberCell TherapyPreclinical StudyBaseTranslating
Grant awards (25)
Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment$611,800
U01 · FY2025 · CA
GMP Manufacturing$183,497
P30 · FY2025 · CA · contact PI
Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment$609,851
U01 · FY2024 · CA
GMP Manufacturing$182,829
P30 · FY2024 · CA · contact PI
Optimizing GVHD Prevention with Systems Pharmacology Models$588,002
U01 · FY2023 · CA · contact PI
Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment$575,395
U01 · FY2023 · CA
GMP Manufacturing$143,994
P30 · FY2023 · CA · contact PI
Optimizing GVHD Prevention with Systems Pharmacology Models$588,002
U01 · FY2022 · CA · contact PI
GMP Manufacturing Core$173,519
P30 · FY2022 · CA · contact PI
Developmental Cancer Therapeutics$61,763
P30 · FY2021 · CA · contact PI
Developmental Cancer Therapeutics$68,905
P30 · FY2020 · CA · contact PI
GMP Manufacturing Core$168,789
P30 · FY2019 · CA · contact PI
Developmental Cancer Therapeutics$60,080
P30 · FY2019 · CA · contact PI
GMP Manufacturing Core$129,478
P30 · FY2018 · CA · contact PI
Developmental Cancer Therapeutics$46,089
P30 · FY2018 · CA · contact PI
GMP Manufacturing Core$2,083
P30 · FY2018 · CA · contact PI
Developmental Cancer Therapeutics$2,083
P30 · FY2018 · CA · contact PI
Drug Development of Ribonucleotide Reductase Inhibitor$334,117
R01 · FY2012 · CA · contact PI
Synthesis of 2-Aminoimidazole-Based Alkaloids$280,426
R01 · FY2007 · GM · contact PI
Synthesis of 2-Aminoimidazole-Based Alkaloids$287,248
R01 · FY2006 · GM · contact PI
Synthesis of 2-Aminoimidazole-Based Alkaloids$1,300
R01 · FY2006 · GM · contact PI
Synthesis of 2-Aminoimidazole-Based Alkaloids$247,625
R01 · FY2005 · GM
Synthesis of 2-Aminoimidazole-Based Alkaloids$247,625
R01 · FY2004 · GM
SYNTHESES OF BIOLOGICALLY ACTIVE MARINE ALKALOIDS$253,937
R01 · FY2001 · GM
SYNTHESES OF BIOLOGICALLY ACTIVE MARINE ALKALOIDS$249,412
R01 · FY2000 · GM